CIK 0001756262
- Large accelerated filer
TransMedics Group, Inc.
Sign in to watch- Ticker
- TMDX
- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- Phone
- +1 978-552-0900
- Business address
- 200 MINUTEMAN ROAD, ANDOVER, MA, 01810
- Open-market buys, last 90 days
- $109,058
- in 1 filing
- Open-market sales, last 90 days
- $385,464
- in 1 filing
Net −$276,406. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-20 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −250 | 15,746 | ||
| 2024-02-16 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion 10b5-1 | +1,144 | $16.00 | $18K | 15,519 |
| 2024-02-16 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion 10b5-1 | +1,714 | $16.14 | $28K | 17,233 |
| 2024-02-16 | Khayal Tamer I Chief Commercial Officer | Sale 10b5-1 | −2,858 | $90.00 | $257K | 14,375 |
| 2024-02-16 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −1,144 | 0 | ||
| 2024-02-16 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −1,714 | 15,996 | ||
| 2024-02-15 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion 10b5-1 | +776 | $16.00 | $12K | 15,151 |
| 2024-02-15 | Khayal Tamer I Chief Commercial Officer | Sale 10b5-1 | −776 | $90.00 | $70K | 14,375 |
| 2024-02-15 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −776 | 1,144 | ||
| 2024-02-14 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion 10b5-1 | +3,050 | $16.00 | $49K | 17,425 |
| 2024-02-14 | Khayal Tamer I Chief Commercial Officer | Sale 10b5-1 | −3,050 | $90.03 | $275K | 14,375 |
| 2024-02-14 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,050 | 1,920 | ||
| 2024-02-07 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion 10b5-1 | +736 | $16.00 | $12K | 15,111 |
| 2024-02-07 | Khayal Tamer I Chief Commercial Officer | Sale 10b5-1 | −736 | $90.09 | $66K | 14,375 |
| 2024-02-07 | Khayal Tamer I Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −736 | 4,970 | ||
| 2024-02-06 | Basile Edward M Director | Sale 10b5-1 | −5,773 | $86.27 | $498K | 9,734 |
| 2024-02-06 | Basile Edward M Director | Sale 10b5-1 | −1,384 | $86.83 | $120K | 8,350 |
| 2024-02-01 | Gordon Stephen Chief Financial Officer | Exercise or conversion 10b5-1 | +8,833 | $13.28 | $117K | 21,908 |
| 2024-02-01 | Gordon Stephen Chief Financial Officer | Exercise or conversion 10b5-1 | +3,644 | $16.14 | $59K | 25,552 |
| 2024-02-01 | Gordon Stephen Chief Financial Officer | Exercise or conversion 10b5-1 | +2,523 | $38.46 | $97K | 28,075 |
Page 21 of 38 · 744 trades